Roche has obtained approval from the U.S. Food and Drug Administration (FDA) for Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) utilizing Halozyme’s ENHANZE drug delivery technology.   Tecentriq Hybreza can be administered subcutaneously in about 7 minutes, in contrast to the standard intravenous (IV) infusion of Tecentriq (atezolizumab), which takes 30-60 minutes. This treatment will be available in the U.S. for all approved adult indications of intravenous Tecentriq, including...